Erasca, Inc.
ERASHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Erasca, Inc. focuses on Biotechnology services and products. Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Valued at $3.79B, ERAS is a mid-cap name in its sector. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
Market Cap
$3.79B
Beta
0.68
P/E (TTM)
—
P/E (Fwd)
-21.63
EPS (TTM)
$-0.93
EPS (Fwd)
$-0.56
ROE
-69.9%
ROA
-17.9%
Cash
$243.8M
Total Debt
$46.0M
Free CF
-$212.7M
52W Change
771.4%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $243.8M in cash comfortably exceeding the $46.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$212.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -69.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.68 suggests ERAS is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ERAS.